Author: Pingping Wu
Author: Bin Ding
Author: Li Ye
Author: Yanfen Huang
Author: Jinjun Ji
Author: Li Xu
Author: Yongsheng Fan
Table 2. OPLS-DA score of serum comparisons among groups.
|
Groups |
R2X |
R2Y |
Q2 |
|
GJD/UT |
0.306 |
0.991 |
0.727 |
|
GZ/GJD |
0.378 |
0.994 |
0.796 |
Table 3. Effect of ZBDHD on ATP and CuZn-SOD in cells (`X±s)
|
Con. of ZBDHD (mg/mL) |
ATP (μmol/g protein) |
CuZn-SOD(U/mL) |
|
0 |
5.00±0.045 |
69.24±34.002 |
|
1 |
5.08±0.116 |
73.50±21.495 |
|
20 |
5.28±0.060 |
102.33±28.115* |
|
100 |
5.48±0.382** |
93.04±32.341* |
Note: **P<0.01 in comparison with that of 0 mg/mL ZBDHD
Table 4. Effects of ZBDHD as shown with luciferase activity (`X±s)
|
Target cytokines |
Concentration of ZBDHD (mg/mL) |
|||
|
0 |
1 |
20 |
100 |
|
|
ARE |
0.69±0.010 |
0.72±0.391 |
1.99±0.377** |
1.12±0.213* |
|
HIF-1 |
0.41±0.189 |
0.28±0.047 |
0.27±0.064 |
0.26±0.035 |
|
E2F |
0.40±0.039 |
0.30±0.022 |
0.79±0.616 |
0.39±0.044 |
|
pP53 |
0.12±0.111 |
1.43±0.371*** |
0.20±0.004 |
0.23±0.034 |
|
ISRE |
0.56±0.009 |
0.64±0.145 |
0.53±0.078 |
0.30±0.019 |
|
SRE |
0.81±0.058 |
0.47±0.117 |
0.68±0.067 |
0.21±0.066 |
|
SIE |
0.08±0.023 |
0.02±0.007 |
0.05±0.033 |
0.09±0.025 |
Figure 1. ZBDHD protected the oral mucosa in rats from GJD treatment. Ⅰ. Histological analysis of the oral mucosa. Ⅱ. Immunohistochemical staining of the oral mucosa. A. Tissue image from a rat treated with saline (UT). B. Tissue image from a rat treated with GJD (GJD). C. Tissue image from a rat treated with ZBDHD after GJD treatment (ZBDHD). D. The expression of NF-κB in 293T, which stimulated by GJD (0, 1, 10, 20 and 50 mg/mL). E. Expression of NF-κB in rat oral mucosa of GJD and GZ groups.
Figure 2. Differentially expressed metabolites in rat serum. Unitless peak heights (int.) show relative intensities in this figure. ▲▲▲ means significantly statistical difference between UT group vs Ganjiangfuzirougui decoction (GJD)group, P<0.001. ● showed difference difference Ganjiangfuzirouguigroup vs Ganzhi (GJD&ZBDHD) group; ●● means statistical difference (P< 0.01), ●●● means significantly statistical difference P<0.001. The variable importance in the projection value (VIP, threshold>1) of the OPLS-DA model was adopted in this project, and the P value of the t-test (P < 0.05) was also used to search for differentially expressed metabolites. The qualitative method to determine the differentially expressed metabolites involved searching the online database (METLIN) (to compare charge ratios determined by mass spectrometry or precise molecular mass).
Figure 3. The changes of the oxygen consumption rate in 293T cells with different ZBDHD treatment. The oxygen consumption rate is presented on the Y-axis, and the concentration of the ZBDHD is presented on the X-axis; values are compared against those of the 0 mg/mL group, * P<0.05.
Figure 4. Transcription of cytokines, Nrf2, Maf and Keap1, influenced by different concentration ZBDHD in 293T cells. (A) Expression of nrf2 mRNA. (B) Expression of maf mRNA.(C) Expression of Keap1 mRNA. The Y-axis presents the mRNA expression level, and the X-axis presents the dose concentration of ZBDHD. Values are compared with those of the (ZBDHD 0 mg/mL) group, *P<0.05, **P<0.01, ***P<0.001.
Publication Date: 20th October 2019
